Do you want to read an article? Please log in or register.
Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis
T Cells
Related content
Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
Ann Rheum Dis.
Kostine M, Finckh A, Bingham CO 3rd, Visser K, Leipe J, Schulze-Koops H, Choy EH, Benesova K, Radstake TRDJ, Cope AP, Lambotte O, Gottenberg JE, Allenbach Y, Visser M, Rusthoven C, Thomasen L, Jamal S, Marabelle A, Larkin J, Haanen JBAG, Calabrese LH, Mariette X, Schaeverbeke T
doi: 10.1136/annrheumdis-2020-217139.
Autoimmune DiseaseT Cells
A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity
J Autoimmun.
Kumar P, Bhattacharya P, Prabhakar BS
doi: 10.1016/j.jaut.2018.08.007.
ImmunotherapyT Cells
Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells
J Autoimmun.
Alissafi T, Hatzioannou A, Legaki AI, Varveri A, Verginis P
doi: 10.1016/j.jaut.2019.102310.
T Cells
Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer
J Autoimmun
Calabrese LH, Caporali R, Blank CU, Kirk AD
doi: 10.1016/j.jaut.2020.102546
Immunotherapy
Long-term immune-related adverse events after discontinuation of immunotherapy
Immunotherapy
Horisberger K, Portenkirchner C, Rickenbacher A, Biedermann L, Gubler C, Turina M
doi: 10.2217/imt-2020-0320
Autoimmune Disease
Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis
Rheumatology (Oxford).
Khoo JK, Barnes H, Key S, Glaspole IN, Östör AJ
doi: 10.1093/rheumatology/keaa117.
COMMENTED
Immunotherapy
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy
★ 3
Recommended and commented by
Prof. Dr Dr Sacha Rothschild, Faculty Member
Eur J Cancer
Ghisoni E, Wicky A, Bouchaab H, Imbimbo M, Delyon J, Gautron Moura B, Gérard CL, Latifyan S, Özdemir BC, Caikovski M, Pradervand S, Tavazzi E, Gatta R, Marandino L, Valabrega G, Aglietta M, Obeid M, Homicsko K, Mederos Alfonso NN, Zimmermann S, Coukos G, Peters S, Cuendet MA, Di Maio M, Michielin O
doi: 10.1016/j.ejca.2021.03.010
Further Publications Rheumatology
Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer
Arthritis Rheumatol
Cunningham-Bussel A, Wang J, Prisco LC, Martin LW, Vanni KMM, Zaccardelli A, Nasrallah M, Gedmintas L, MacFarlane LA, Shadick NA, Awad MM, Rahma O, LeBoeuf NR, Gravallese EM, Sparks JA
doi: 10.1002/art.41949
Immunotherapy
Is autoimmunity the Achilles' heel of cancer immunotherapy?
Nat Med.
June CH, Warshauer JT, Bluestone JA
doi: 10.1038/nm.4321.